Backgrounds: Despite the clinical success of taxanes, they still have limitations, such as chemoresistance. To overcome the limitations of paclitaxel, genetic alterations and targeting effects of altered genes were observed in paclitaxel-resistant cancer. Because paclitaxelresistant cancer shows high levels of Plk1, a promising target in chemotherapy, the effectiveness of Plk1 inhibitors in paclitaxel-resistant cancer cells has been investigated. Methods: Paclitaxel-resistant cancer cells were developed by exposure of stepwise escalating levels of paclitaxel. Genetic alterations were detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and immunoblotting. Using a cell viability assay, combined targeting effects for Plk1 and androgen receptor (AR) were determined. Clinical data were analyzed to understand the relationship between Plk1 and AR in prostate cancer patients. Results: Treatment with Plk1 inhibitors markedly reduced the expression of MDR1, MRP1, and Plk1 in the paclitaxel-resistant cancer. Among Plk1 inhibitors, genistein, recently found as a direct Plk1 inhibitor, tended to be more effective in the paclitaxel-resistant prostate cancer than the parental cancer cells, which was related to the suppression of the AR, as well as inhibition of Plk1 activity. A combination of Plk1 inhibitors and AR antagonist bicalutamide exhibited a synergistic effect in LNCaP TXR , as well as LNCaP cells, by inhibiting Plk1 and AR. Analysis of clinical data provides evidence for the relevance between Plk1 and AR in prostate cancer patients, showing that Plk1 and AR are strong predictors of poor survival rates. Conclusions: We suggest that cotargeting Plk1 and AR would be effective in advanced chemoresistant prostate cancer cells to overcome the limitations associated with paclitaxel.
Introduction
Antimitotic therapies targeting microtubule dynamics, such as vinca alkaloids and taxanes, are widely used for the treatment of cancer. [1] [2] [3] [4] Taxanes are still the first choice of treatment for several solid malignant tumors, and taxanes in combination with other chemotherapy agents are standard in patients with advanced prostate cancer, 5, 6 breast cancer, 7 ovarian cancer, 3 and non-small cell lung cancer. 4 Despite the clinical success of taxanes, they still have limitations, such as the acquisition of resistance and dose-dependent toxicity. 1, 8, 9 Acquired taxane resistance is a serious clinical obstacle in effectively treating cancer patients. High expression levels of ABCB1, also known as p-glycoprotein or multidrug resistance protein 1 (MDR1), and multidrug resistance-associated protein 1 (MRP1; ABCC1) are thought to be one of the causes of paclitaxel resistance. 8, 10 To reduce these limitations, combination chemotherapy has been broadly investigated via in vitro experiments, in vivo studies, and clinical trials. The use of new antimitotic drugs as targeted therapies can offer the possibility to overcome some of the limitations of current antimitotic drugs.
Recently, Polo-like kinase 1 (Plk1) has drawn attention in the development of antimitotic drugs to treat cancer. 11 The overexpression of Plk1 in several malignant solid tumors, including breast, 12, 13 colon, 14 non-small cell lung, 15 and prostate cancers, 16, 17 is correlated with tumorigenicity. Plk1 has been shown to be involved in chemoresistance, and Plk1 inhibition may overcome the drug resistance induced by several anticancer drugs, including doxorubicin, 18 ,19 gemcitabine, 20 and docetaxel. 21 Plk1-targeted therapies could possibly reduce or eliminate the chemoresistance in chemotherapeutics. In addition, castration-resistant prostate cancer cells are sensitive to Plk1 inhibition by the repression of the androgen signaling pathway, according to recent studies. 22, 23 Because prostate cancer is an androgen-dependent disease, therapeutic approaches are directed toward androgen ablation for advanced and metastatic prostate cancer, which shows initial improvement in the patients. 24, 25 Taxanes are one of the therapeutic options for patients who receive androgen ablation therapies. 26, 27 However, the inappropriate activation of androgen receptor (AR) signaling induces a relapse with a more aggressive and castration-resistant form of prostate cancer, which does not require circulating androgens, but still depends on functional AR for tumor growth. 25, 28 According to the proposal of Liu and colleagues, Plk1 inhibitors might have therapeutic potential for patients with castration-resistant prostate cancer at this stage. 22, 23 As part of the effort to find Plk1-targeting agents, Plk1-specific inhibitors, such as volasertib, BI 2536, and GSK461364, have been developed for chemotherapeutics. We recently found genistein to be a direct inhibitor of Plk1 kinase. 29 Although the majority of studies have shown that genistein induces mitotic arrest, [30] [31] [32] [33] previous studies focused on genistein as a tyrosine kinase epidermal growth factor receptor (EGFR) inhibitor, 34 and did not clearly explain how genistein induced mitotic arrest as an EGFR inhibitor. The discovery that genistein is a Plk1 inhibitor, provides a mechanism for the mitotic arrest and apoptosis induced by genistein in human cancer cells. 29 In addition, genistein has also been identified as a suppressor of AR expression and activity in prostate cancer. 35 We hypothesized that the Plk1 inhibitor genistein would be effective in cancers with overexpression of AR and Plk1. For this, paclitaxel-resistant cancer cells were developed to test whether paclitaxel-resistant cells were sensitive to Plk1 inhibitors, because paclitaxel is a therapeutic option for patients with advanced prostate cancer and non-small cell lung cancer, and the recurrence of these cancers exhibits greater aggressiveness. 26, 27, 36 Here, we demonstrated that treatment with Plk1 inhibitors including volasertib, BI 2536, and genistein markedly reduced the levels of MRP1, MDR1, and Plk1 in the paclitaxel-resistant cancers. Compared with other Plk1 inhibitors, genistein has suppressive effects against Plk1 and AR expression in paclitaxel-resistant prostate cancer cells. In addition, the combined effects of Plk1 inhibitors and an AR antagonist bicalutamide on cell growth in paclitaxel-resistant LNCaP TXR cells, were evaluated to investigate the possibility to overcome some of the limitations associated with current antimitotic drugs.
Materials and methods

Materials
Dulbecco's modified Eagle's medium (DMEM), Roswell Park Memorial Institute (RPMI)-1640, Minimum Essential medium (MEM), fetal bovine serum, penicillin, and streptomycin were purchased from Corning Cellgro (Manassas, VA, USA). BI 2536 and volasertib were purchased from Selleck Chemicals (Houston, TX, USA). Genistein, paclitaxel, bicalutamide, and all other chemical reagents were purchased from SigmaAldrich (St. Louis, MO, USA).
Cell culture and establishment of paclitaxelresistant cancer cells
Human prostate cancer LNCaP (clone FGC, #21740), DU145 (#30081), and lung cancer NCI-H460 cells (#30177) were purchased from the Korean Cell Line Bank (KCLB; Seoul, Korea) and were authenticated before being frozen by KCLB using short tandem repeats (STR). Human prostate cancer LNCaP and lung cancer NCI-H460 cells were cultured at 37°C in a 5% CO 2 humidified atmosphere in RPMI-1640 medium, supplemented with 10% (v/v) heat-inactivated fetal bovine serum, 100 units/ml penicillin, and 100 µg/ml streptomycin. Human prostate cancer DU145 cells were cultured in MEM. NCI-H460, LNCaP, and DU145 cells were exposed to stepwise escalating levels of paclitaxel to develop paclitaxel-resistant cells. The concentration of paclitaxel increased twofold at each step of resistance from 1 nM up to 20 nM. The resistant cells Supplementary Table 4 .
Fluorescence-activated cell sorting analysis
To determine the percentage of cells in each phase of the cell cycle, cells were collected by trypsinization, fixed in 75% ethanol, stained with 30 μg/ml propidium iodide solution, and subjected to fluorescence-activated cell sorting (FACS) analysis as described previously. 37 Cells were sorted using a Guava easyCyte TM FACS machine (Millipore; Billerica, MA, USA), and data were analyzed with Incyte TM software (Millipore).
Immunoblot analysis
For immunoblotting, cell extracts were prepared in lysis buffer (10 mM HEPES [pH 7.4], 5 mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid, 10 mM KCl, 2 mM MgCl 2 , 40 mM β-glycerophosphate, 1 mM dithiothreitol, 1 mM phenyl methyl sulfonyl fluoride, 25 µg/ml leupeptin, and 5 µg/ml pepstatin A) as described previously. 29, 38 Lysates were centrifuged at 12,000 rpm for 15 min at 4°C, and the supernatants were collected and the protein concentrations adjusted. Then, cell lysates were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis prior to immunoblot analysis. Immunoblotting was performed with anti-p-S46-TCTP (Cell Signaling Technology, 5251), anti-TCTP (Santa Cruz Biotechnology, Dallas, TX, USA), anti-p-T210-Plk1 (Cell Signaling Technology, 5472), anti-Plk1 (Millipore, Bedford, MA, USA; 05-844), and anti-actin (Sigma-Aldrich) antibodies using an Odyssey infrared imaging system (LI-COR Biosciences; Lincoln, NE, USA) and LI-COR Odyssey software.
Statistical analysis
All data are given as means ± standard deviations from at least three independent experiments. Results were analyzed for statistically significant differences using Student's t test, and a p value <0.05 was considered statistically significant. Correlation of mRNA-mRNA pairs of the gene set in cell lines or human prostate tumors were analyzed calculating the Pearson correlation coefficient. Statistical significance is presented in figure legends: *p < 0.05; **p < 0.01; ***p < 0.001. Drug combination was analyzed by the combination index (CI) method using CompuSyn software (ComboSyn Inc., NJ, USA) 39 ; CI<0.9 indicates synergism, CI=0.9-1.1 additivity, and CI>1.1 antagonism.
Gene set enrichment analysis and correlation analyses
The human prostate cancer patients' microarray dataset was obtained from the NCBI-GEO database (GSE16560, GSE70769). To evaluate the correlation of the gene expression with overall survival (OS) or relapse-free survival (RFS), patients were separated into two subgroups, 'gene expression high' or 'gene expression low'. Total of 281 prostate cancer patients (alive 75, dead 206) were selected (GSE16560), according to clinical stage T1-T2, Mx, and N0. 40 From these 281 cases, 150 men were selected, depending on the expression levels of Plk1, AR, or prostate-specific antigen (PSA) with the top 75 samples with the highest expression and the lowest 75 samples with lowest expression of Plk1, AR, or PSA. In the GSE70769 dataset, a total of 94 prostate cancer patients were in samples in the validation cohort only, with complete analysis. 41 From the 94 cases, 80 men were selected, depending on the expression levels of Plk1, AR, or PSA with the top 40 samples with the highest expression and the bottom 40 samples with the lowest expression of Plk1, AR, or PSA. A total 150 and 80 prostate cancer patients with subtype classification were used to analyze the correlation of gene expression and OS rate or RFS rate. Kaplan-Meier survival analysis and a log-rank test were used to evaluate the statistical significance of survival differences between the two groups. Correlations of mRNA expression of genes in the gene set for human prostate cancer were analyzed using the GSE70769 dataset. 41 From total of 94 prostate cancer patients, we defined two subgroups, 'gene set high' or 'gene set low', depending on the expression levels of Plk1 with the top 10 samples with the highest expression and the low 10 samples with lowest expression of Plk1. Heat maps were generated using the GENE-E software (Broad Institute). GSEA was performed using the Broad Institute platform (http://www.broadinstitute.org/gsea/index.jsp). Patient samples were selected and grouped for high or low mRNA expression of the selected gene or gene set. All percentiles between the lower and upper quartiles were computed and the best performing threshold was used as cutoff ±1.5. The median was calculated over the entire dataset.
Results
Plk1 is highly expressed and activated in paclitaxel-resistant cancer cells
To overcome the limitations of paclitaxel, paclitaxel-resistant LNCaP TXR and NCI-H460 TXR cells were established by treatment with paclitaxel as described in the Materials and Methods section. The GI 50 values of paclitaxel in the LNCaP TXR cells and NCI-H460 TXR cells were 130 and 204 nM, respectively, which were over 10 times higher than the GI 50 values of paclitaxel in the parental LNCaP and NCI-H460 cells (Supplementary Figure 1) , indicating that the resistance indexes were over 10. Because the high expression levels of MDR1 and MRP1 are thought to be the main mechanism of chemoresistance acquisition, 8, 10 the mRNA levels of MDR1 ( Figure 1a ) and MRP1 ( Figure 1b) were observed in the paclitaxel-resistant LNCaP TXR and NCI-H460 TXR cells by qRT-PCR. As expected, the mRNA levels of MDR1 and MRP1 in the paclitaxel-resistant cells were over 10 times greater than those found in the parental cells.
As paclitaxel induces mitotic arrest when a mitotic kinase Plk1 peaks, the levels of Plk1 mRNA were Then, we wanted to understand the reason why LNCaP TXR cells are sensitive to the treatment by genistein (Figure 2a ), although the levels of Plk1 were increased in both that of paclitaxel-resistant NCI-H460 TXR and LNCaP TXR cells. Recent studies have shown that Plk1 inhibition represses the androgen signaling pathway in prostate cancer 22, 23, 42 and that genistein downregulates AR in prostate cancer. 35 Based on these studies, we addressed whether genistein affects to the androgen signaling pathway. For this, the expression of AR mRNA was observed in LNCaP TXR and NCI-H460 TXR cells, as measured by qRT-PCR ( Figure  2b ). The results showed that the levels of AR mRNA in LNCaP TXR cells were approximately 16 times higher than those of the parental LNCaP cells (Figure 2b ; left panel). However, the levels of AR mRNA in NCI-H460 TXR cells, were only twice as high as those of the parental NCI-H460 cells (Figure 2b ; middle panel). In addition, basal levels of AR mRNA in prostate cancer were much higher than those in lung cancer (Figure 2b ; right panel), although AR functions in several organs, including the lung. 43, 44 Because AR mRNA was lower in NCI-H460 cells, the effects of genistein on AR signaling were focused on prostate cancer rather than lung cancer. To compare the effects of Plk1 inhibitors with AR antagonists on AR signaling in paclitaxel-resistant prostate cancer, the cytotoxic effects of bicalutamide, a specific AR antagonist, were measured in LNCaP and LNCaP TXR cells (Figure 2c) . A cell viability assay showed that bicalutamide was more effective in the paclitaxel-resistant LNCaP TXR cells expressing high levels of AR, with a GI 50 of 9.1 µM, than that of LNCaP cells ( Figure 2c ).
Next, to understand the effects on the expression of AR and its target, PSA, from treatment with Plk1 inhibitors or the AR antagonist bicalutamide in LNCaP and LNCaP TXR cells, qRT-PCR was performed after treatment with BI 2536, volasertib, genistein, or bicalutamide at the GI 50 in LNCaP and LNCaP TXR cells (Figure 2d ). The results showed that the mRNA levels of AR were reduced by treatment with BI 2536, volasertib, or bicalutamide compared with those of the control in LNCaP TXR cells (Figure 2d) . Notably, by treatment with genistein, the mRNA levels of AR in the LNCaP TXR cells were markedly reduced to approximately 95-fold lower than those of the control (control 17.5 versus genistein 0.183; Figure 2d ). In addition, the treatment of bicalutamide reduced the AR mRNA levels approximately 35-fold lower than those of the control (control 17.5 versus bicalutamide 0.491). The expression of PSA, a transcriptional target of AR, was effectively suppressed by treatment with (Figure 3a) , under the condition when mRNA levels of AR in DU145 TXR cells were evaluated by qRT-PCR. AR mRNA in DU145 TXR cells was upregulated by a factor of approximately eight compared with that of the parental DU145 cells (Figure 3b, left panel) . Although the basal levels of AR in DU145 cells were low, acquiring the resistance against paclitaxel in DU145 TXR cells, upregulated the expression of AR mRNA (Figure 3b, right panel) . In addition, mRNA levels of MDR1, MRP1, and Plk1 in DU145 TXR cells were higher by approximately 7-10 times compared with those of DU145 cells as expected (Figure 3c ). When the cell viability after treatment with BI 2536, volasertib, genistein, or bicalutamide was evaluated in a concentration-dependent manner in both DU145 and DU145 TXR cells (Figure 3d) (Figure 4e ). These data indicated that paclitaxelresistant prostate cancer cells were more sensitive to genistein and undergo apoptotic cell death more easily, compared with the parental prostate cancer cells, through mitotic arrest.
Next, we wanted to understand how genistein is more effective in paclitaxel-resistant prostate cancer cells than parental cells. Because the levels of mRNA, protein, and the active form (phosphorylated form at T210) of Plk1 were higher in LNCaP TXR cells than in the parental cells ( Figure  1c and d) , we wanted to determine whether the activity of Plk1 in LNCaP TXR cells was inhibited more sensitively by the treatment with genistein. The levels of the phosphorylated form TCTP, an endogenous substrate of Plk1, were detected by immunoblot analysis using antibodies against p-TCTP and TCTP (Figure 4f ). In LNCaP TXR cells, treatment of genistein markedly reduced the levels of phosphorylated TCTP, compared with those of LNCaP cells (Figure 4f ). In addition, the levels of p-Plk1 and Plk1 were markedly reduced by treatment of genistein in LNCaP TXR cells expressing high levels of Plk1. Thus, genistein reduced the activity and expression of Plk1 more effectively in LNCaP TXR cells. Altogether, genistein induced apoptosis more effectively in paclitaxel-resistant prostate cancer cells through suppression of Plk1 activity and expression.
Plk1 inhibitors markedly suppressed the expression of MRP1, a key factor of chemoresistance, in LNCaP TXR cells
Multidrug resistance genes MRP1 and MDR1 are key factors that explain the poor response to treatment of cancer patients, 46 and Plk1 inhibition overcomes the drug resistance induced by 
Clinical relevance of Plk1 and AR in prostate cancer patients
We further investigated the translational and clinical relevance of Plk1 and AR in prostate cancer patients by analyzing human prostate cancer data sets (GSE16560, GSE70769). We analyzed the correlation between the expression of Plk1, AR, and PSA, and the survival rates in prostate cancer patients ( Figure 7, a-b) . The expression of Plk1 mRNA and cumulative OS rates (Figure 7a ) or RFS rates ( Figure 7b ) were inversely correlated in human prostate cancer (Figure 7, a-b) , indicating high expression of Plk1 mRNA reflected the poor prognostic value in prostate cancer patients. In addition, we analyzed expression of AR in prostate cancer patients and their survival rates, because the response of prostate cancer patients is different, depending on the presence of AR. Similarly, the mRNA expression of AR or its transcriptional target PSA is inversely correlated with cumulative OS rates (Figure 7a ) or RFS rates (Figure 7b ) in human prostate cancer. Although the survival rates were dependent on both the levels of AR and PSA, overexpression of AR and survival rates were more correlated compared with those of PSA. Thus, the overexpression of Plk1 or AR reflects the poor prognosis in prostate cancer patients.
To define the correlation between Plk1 and AR gene expression, the heat map analysis was performed in prostate cancer patients' samples (GSE70769). The tumor samples expressing high levels of Plk1 were defined as 'gene set high', compared with tumors expressing low levels of Plk1 defined as 'gene set low.'. The analysis showed that the expression of mRNA between the expression of AR and Plk1 was positively correlated in prostate cancer patients (Figure 7c) . Thus, analysis of clinical patients' data provided evidence for a particular clinical relevance of our findings in AR-positive prostate cancer, showing that Plk1 is a strong predictor of poor OS and RFS in prostate cancer patients.
Discussion
Taxanes in combination with other chemotherapy medicines are standard in patients with advanced cancers of the prostate, 5, 6 breast, 7 ovary, 3 and lung. 4, 8 Although there are many positive aspects of the agents, some malignancies acquire drug resistance through the expression of MDR1 or MRP1, which is thought to be the main cause of resistance to taxanes. 8, 47 and DU145 TXR cells acquired resistance to paclitaxel, they were still sensitive to Plk1 inhibitors, which may be due to the inhibitory effect on the expression and activity of Plk1. Furthermore, paclitaxel-resistant prostate cancer cells showed high levels of AR and PSA mRNA compared with those of parental cells, which was downregulated by treatment with Plk1 inhibitors and AR antagonist (see Figure 8 ). Recent standard chemotherapy used in prostate cancer is docetaxel rather than paclitaxel of taxanes. 48 The docetaxel-resistant mechanisms would be similar with those of paclitaxel because of the similar action mechanisms of taxanes. 49 According to recent studies, Plk1 inhibition represses the androgen signaling pathway in prostate cancer. 22 Figure 7) . Thus, Plk1 and AR are useful as valuable prognostic markers in advanced prostate cancer patients.
The combination effect between Plk1 inhibitors and the AR antagonist bicalutamide was determined by CI in both prostate cancer and paclitaxel-resistant prostate cancer. The strongest synergic effects were detected in the combination between volasertib and 5.5 μM bicalutamide in both parental prostate cancer and paclitaxelresistant prostate cancer cells with CI values of 0.5868 and 0.6818, respectively (see Table 1 
